Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 May;69(5):914–917. doi: 10.1038/bjc.1994.176

Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).

N P O'Rourke 1, E V McCloskey 1, S Rosini 1, R E Coleman 1, J A Kanis 1
PMCID: PMC1968914  PMID: 8180023

Abstract

Twenty patients with hypercalcaemia due to malignancy, which persisted following rehydration, were treated with the bisphosphonate, aminohexane bisphosphonate (AHBP), which is structurally similar to pamidronate. The treatment given was a single infusion of 125 mg of AHBP in 500 ml of normal saline infused over 4 h. Serum and urine biochemistry were measured before and after treatment. Acute toxicity was evaluated with particular attention to gastrointestinal symptoms, acute-phase reaction and change in renal function, as judged by serum creatinine. The infusion of AHBP induced a rapid fall apparent by day 3 (P < 0.001), with a nadir at day 7. The serum calcium remained lower at days 14 and 28 than at day 0, but the numbers followed up were low (n = 5 and n = 4). In all 20 patients there was a fall in serum calcium after treatment, and in 13 (65%) normocalcaemia was achieved. Failure to respond completely to AHBP appeared to be associated with a renal mechanism of hypercalcaemia. Treatment was associated with a significant decrease in fasting urinary calcium excretion (P < 0.05). There was no change in white cell count or renal function following AHBP and only two cases of mild pyrexia after infusion. We conclude that aminohexane bisphosphonate is an effective agent in the treatment of tumour-induced hypercalcaemia, with rapid onset of effect and low toxicity.

Full text

PDF
914

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S., Bhalla A. K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., Lo Cascio V. The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987 Dec;41(6):326–331. doi: 10.1007/BF02556671. [DOI] [PubMed] [Google Scholar]
  2. Atkins R. M., Yates A. J., Gray R. E., Urwin G. H., Hamdy N. A., Beneton M. N., Rosini S., Kanis J. A. Aminohexane diphosphonate in the treatment of Paget's disease of bone. J Bone Miner Res. 1987 Aug;2(4):273–279. doi: 10.1002/jbmr.5650020403. [DOI] [PubMed] [Google Scholar]
  3. Bonjour J. P., Rizzoli R. Pathophysiological aspects and therapeutic approaches of tumoral osteolysis and hypercalcemia. Recent Results Cancer Res. 1989;116:29–39. doi: 10.1007/978-3-642-83668-8_2. [DOI] [PubMed] [Google Scholar]
  4. Coleman R. E., Woll P. J., Miles M., Scrivener W., Rubens R. D. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer. 1988 Nov;58(5):621–625. doi: 10.1038/bjc.1988.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gallacher S. J., Ralston S. H., Patel U., Boyle I. T. Side-effects of pamidronate. Lancet. 1989 Jul 1;2(8653):42–43. doi: 10.1016/s0140-6736(89)90277-8. [DOI] [PubMed] [Google Scholar]
  6. Mautalen C. A., Casco C. A., Gonzalez D., Ghiringhelli G. R., Massironi C., Fromm G. A., Plantalech L. Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases. Br Med J (Clin Res Ed) 1984 Mar 17;288(6420):828–829. doi: 10.1136/bmj.288.6420.828-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. O'Rourke N. P., McCloskey E. V., Vasikaran S., Eyres K., Fern D., Kanis J. A. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer. 1993 Mar;67(3):560–563. doi: 10.1038/bjc.1993.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Percival R. C., Yates A. J., Gray R. E., Galloway J., Rogers K., Neal F. E., Kanis J. A. Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) 1985 Sep 21;291(6498):776–779. doi: 10.1136/bmj.291.6498.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ralston S. H., Alzaid A. A., Gallacher S. J., Gardner M. D., Cowan R. A., Boyle I. T. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Q J Med. 1988 Oct;68(258):825–834. [PubMed] [Google Scholar]
  10. Ralston S. H., Gallacher S. J., Patel U., Dryburgh F. J., Fraser W. D., Cowan R. A., Boyle I. T. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989 Nov 18;2(8673):1180–1182. doi: 10.1016/s0140-6736(89)91791-1. [DOI] [PubMed] [Google Scholar]
  11. Rizzoli R., Buchs B., Bonjour J. P. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer. 1992 Mar 12;50(5):706–712. doi: 10.1002/ijc.2910500507. [DOI] [PubMed] [Google Scholar]
  12. Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 1983;35(1):87–99. doi: 10.1007/BF02405012. [DOI] [PubMed] [Google Scholar]
  13. Thiebaud D., Jaeger P., Burckhardt P. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone. J Bone Miner Res. 1990 Mar;5(3):221–226. doi: 10.1002/jbmr.5650050304. [DOI] [PubMed] [Google Scholar]
  14. van Holten-Verzantvoort A. T., Bijvoet O. L., Cleton F. J., Hermans J., Kroon H. M., Harinck H. I., Vermey P., Elte J. W., Neijt J. P., Beex L. V. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987 Oct 31;2(8566):983–985. doi: 10.1016/s0140-6736(87)92555-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES